Topics:

Patent Granted for MoAbs Used in Neoprobe's RIGScan Products

Patent Granted for MoAbs Used in Neoprobe's RIGScan Products

DUBLIN, Ohio--Neoprobe Corporation has announced that a patent granted to Jeffrey Schlom, PhD, of the National Cancer Institute, and David Colcher, PhD, of the University of Nebraska Medical Center, covers claims to composition of matter for a large group of second-generation monoclonal antibodies that target the tumor-associated antigen TAG-72.

Neoprobe holds an exclusive global license for use of these antibodies with its RIGS technology for surgical detection and treatment of cancer. The antibodies named in the patent include CC49, a component of Neo-probe's first commercial product, RIGScan CR49, currently under investigation for colorectal cancer.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.